3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
4
Completed
3
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma
2
Hematologic Neoplasms
2
Subcutaneous panniculitis-like T-cell lymphoma
1
Sezary Syndrome
1
Recurrence
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Infectious Mononucleosis
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Rituximab
21
Cyclophosphamide
15
Etoposide
11
Vincristine
9
Prednisone
9
Doxorubicin
8
Cytarabine
8
Filgrastim
7
Radiotherapy
6
Peripheral Blood Stem Cell Transplantation
6
fludarabine phosphate
5
Melphalan
5
Dexamethasone
4
Carmustine
4
Bendamustine Hydrochloride
4
loncastuximab tesirine
3
ibrutinib
3
Tacrolimus
3
Stem Cell Transplantation
3
Mycophenolic Acid
3
Methotrexate
3
Gemcitabine
3
Calcium Dobesilate
3
CT-P10
3
Busulfan
3
venetoclax
2
sargramostim
2
polatuzumab vedotin
2
pembrolizumab
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma, Large B-Cell, Diffuse
×
Brentuximab Vedotin
×
Clear all
NCT02623920
2017-05-19
S-BR
University of Arizona
Phase 2
Withdrawn